OR WAIT null SECS
October 30, 2018
The acquisition will allow Lonza to further develop technology for scalable autologous cell-therapy manufacturing.
October 10, 2018
The companies will develop and commercialize ARO-HBV, a Phase I/II subcutaneous, ribonucleic acid interference therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.
The companies signed a three-year clinical manufacturing agreement to manufacture GlaxoSmithKline’s specific peptide enhanced affinity receptor T-cell receptor therapy for United States, Canadian, and European clinical trials.
September 27, 2018
GE Healthcare, Cobra Biologics, and the Centre for Process Innovation (CPI) have entered into a collaboration to advance manufacturing of adeno-associated virus vectors for gene therapy.
September 24, 2018
FDA awarded nearly $3 million in grants for continuous manufacturing and other advanced manufacturing technologies as part of the agency’s efforts to ensure a robust and reliable supply of biological products.
September 20, 2018
The CHF 400-million (US$416-million) investment in Lonza's biopark in Visp, Switzerland, will expand Ibex Solutions with two new offerings, drug substance development and drug substance and drug product manufacturing.
September 07, 2018
Bio-Rad introduces CHT Ceramic Hydroxyapatite XT media and Nuvia HP-Q resin resin for process protein purification.
August 09, 2018
The combined companies will provide research- and clinical-grade human immune cells, blood products, and related services.
August 08, 2018
Avalon and Weill will co-develop bio-production and standardization procedures for CAR-T therapy.
August 06, 2018
The companies will collaborate on the discovery, development, and commercialization of cell therapies for cancer.